- Home
- VIDA vs INKT Comparison
VIDA vs INKT Comparison
Compare VIDA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.73
HOLD
Current Price
$10.55
Company Overview
Basic Information| Metric | VIDA | INKT |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 53.9M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VIDA | INKT |
|---|---|---|
| Price | $2.73 | $10.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 107.0K | 11.1K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $8.48 |
| 52 Week High | $4.25 | $18.17 |
Technical Indicators
Market Signals| Indicator | VIDA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 44.07 |
| Support Level | $2.14 | $9.47 |
| Resistance Level | $2.89 | $12.61 |
| Average True Range (ATR) | 0.36 | 0.63 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 60.78 | 23.74 |
Price Performance
Historical Comparison VIDA
INKT
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.